about
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.How to treat old MCL patients: one size fits it all?A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia.Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.How to manage mantle cell lymphoma.Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells.Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes.Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience.New paradigms in mantle cell lymphoma: is it time to risk-stratify treatment based on the proliferative signature?Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival.Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis.HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data.Data quality improvement of a multicenter clinical trial dataset.Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up.Highly sensitive MYD88L265P mutation detection by droplet digital PCR in Waldenström Macroglobulinemia.Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders.A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial.Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma.Novel CALR somatic mutations in essential thrombocythaemia.Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia.Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma.Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP programInternational, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman diseaseTime to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for deathMinimal Residual Disease in Indolent Lymphomas: A Critical AssessmentNew Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid MalignanciesA Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana LinfomiBendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective studyEarly progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 studyObinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana LinfomiA B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines
P50
Q33437445-593F25DE-9244-41B4-ADF3-826BDECDFF47Q34077752-C5040886-DA4A-4E51-B22F-6AF0233EF97EQ34663596-1A38D2A3-DBBC-44EF-8649-623AA5F8E0BEQ34973576-FA586AD2-1DBB-4DE4-81A0-AE2FC2AF0924Q35759705-F458D5B6-DC6F-40B1-A464-62B7488E8A57Q37701511-CF4FC5B8-7046-4B26-99E7-FA0B61A25478Q39187610-6C2226A4-8316-4C6E-9A7C-30BD5150F49BQ39628753-CA70EDDD-8696-4FA2-9445-D42639FDA2D1Q42064478-3D659C30-EF1F-4D11-963C-FC142B6EA15FQ42120007-EE3C4A9D-DCD7-4D92-9C26-ACEA9A1995F7Q42336329-DE389329-D4C2-4037-997D-4E65339E4570Q42348448-FA227ACE-A660-454F-9751-56150F658501Q42848307-179B6539-3780-4714-9A9D-3155691517C2Q43623431-5B9B7C90-9441-4662-999F-2D239B415044Q43837244-44142D9C-9247-4251-8FFE-53614DAC245FQ45785426-D008B1F7-1B9A-4EE0-A44E-C2CE731CFE00Q47367539-AD7527BE-F66A-40F9-BD77-416750475A0CQ47423302-C0447D2C-1F92-4D84-ACA2-BD0286933E60Q47740429-14FD68E7-E27D-452D-B2AD-33A74483EEEFQ48276956-FDEDAF9C-4D08-4918-8C30-964171FCCEA5Q48335780-14E9C626-39A6-4922-9F4B-9460144F193CQ52641888-9086AE6E-AB36-4987-9B9C-787D117EEA9CQ52714899-A3155C65-8259-45F4-8C19-BC132E953FE9Q52730895-24FDC20D-8C3E-4DE5-BF83-CA5F1C2D630DQ52863507-7DABAAC9-A9FA-47B2-8C44-55823B19C760Q52912068-59B3E6EB-7B2A-4B34-994F-A958AA5A11A5Q52919176-F1A3B787-9391-40C9-808A-725B309C9DBFQ52969991-B8AB9A1F-B9B0-4D70-BB8D-170109833F5BQ53137713-41B9ED9A-C69B-4756-8C97-62FD460C1B03Q55380607-42AD7521-044D-4612-80F1-461572260E8AQ56349272-E3503E3D-9589-4855-B062-47B2B6063373Q57161074-2A9EBA9E-4229-4D1B-9A4B-6062D8E5A216Q58577010-EFFE03B1-37DC-4215-99A6-79EDE7ED3897Q58606498-05D84068-19DE-48D3-B79B-C4F4DF5925DAQ58723303-BD9D9E0A-B5E2-4A70-A8A6-3C34226167A8Q88951248-8AFC55BD-FB85-44BB-8CF7-81F11799DC81Q89274814-F9AD2C30-7CBC-4E9B-84AD-2F950461E947Q91774671-034151DA-CCDF-4AF0-93AC-22867FADB053Q91806481-BE48159A-6524-41F6-9DAE-919CB669C66DQ92022521-53C02CF6-A43D-4646-8FE6-1BAF3C0A39D7
P50
description
onderzoeker
@nl
researcher ORCID: 0000-0002-9711-1502
@en
name
Simone Ferrero
@ast
Simone Ferrero
@en
Simone Ferrero
@es
Simone Ferrero
@nl
type
label
Simone Ferrero
@ast
Simone Ferrero
@en
Simone Ferrero
@es
Simone Ferrero
@nl
prefLabel
Simone Ferrero
@ast
Simone Ferrero
@en
Simone Ferrero
@es
Simone Ferrero
@nl
P106
P1153
16678617000
P31
P496
0000-0002-9711-1502